Overview

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety of combining two agents (everolimus and BKM120) for the treatment of advanced cancer arising from solid organ in patients who are no longer benefiting from or unable to withstand standard treatment of these conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborator:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus